Implications for Immunotherapy of Breast Cancer by Understanding the Microenvironment of a Solid Tumor.
breast cancer
cancer-associated fibroblasts
immunotherapy
tumor microenvironment
tumor-associated macrophages
tumor-infiltrating lymphocytes
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Jun 2022
29 Jun 2022
Historique:
received:
11
04
2022
revised:
17
06
2022
accepted:
25
06
2022
entrez:
9
7
2022
pubmed:
10
7
2022
medline:
10
7
2022
Statut:
epublish
Résumé
Breast cancer is poorly immunogenic due to immunosuppressive mechanisms produced in part by the tumor microenvironment (TME). The TME is a peritumoral area containing significant quantities of (1) cancer-associated fibroblasts (CAF), (2) tumor-infiltrating lymphocytes (TIL) and (3) tumor-associated macrophages (TAM). This combination protects the tumor from effective immune responses. How these protective cell types are generated and how the changes in the developing tumor relate to these subsets is only partially understood. Immunotherapies targeting solid tumors have proven ineffective largely due to this protective TME barrier. Therefore, a better understanding of the interplay between the tumor, the tumor microenvironment and immune cells would both advance immunotherapeutic research and lead to more effective immunotherapies. This review will summarize the current understanding of the microenvironment of breast cancer giving implications for future immunotherapeutic strategies.
Identifiants
pubmed: 35804950
pii: cancers14133178
doi: 10.3390/cancers14133178
pmc: PMC9264853
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Br J Cancer. 2021 May;124(11):1759-1776
pubmed: 33782566
J Immunother Cancer. 2021 Jun;9(6):
pubmed: 34117114
J Clin Oncol. 2019 Mar 1;37(7):559-569
pubmed: 30650045
J Hematol Oncol. 2019 Aug 28;12(1):86
pubmed: 31462327
Cold Spring Harb Perspect Med. 2016 Aug 01;6(8):
pubmed: 27481837
Cancer Treat Rev. 2018 Feb;63:122-134
pubmed: 29287242
Eur J Cancer. 2020 Dec;141:162-170
pubmed: 33161240
Sci Transl Med. 2020 Nov 4;12(568):
pubmed: 33148626
Clin Cancer Res. 2018 Feb 1;24(3):511-520
pubmed: 28801472
Cell Rep. 2021 Oct 19;37(3):109844
pubmed: 34686340
Front Immunol. 2018 Mar 08;9:470
pubmed: 29568299
Curr Opin Immunol. 2018 Apr;51:146-153
pubmed: 29605760
Cancer Sci. 2020 Jan;111(1):47-58
pubmed: 31710162
Cancer Treat Rev. 2022 Mar;104:102352
pubmed: 35144055
Biomaterials. 2020 Jan;227:119559
pubmed: 31670078
Integr Biol (Camb). 2015 Oct;7(10):1120-34
pubmed: 25959051
Blood. 2022 Jun 30;139(26):3708-3721
pubmed: 35090171
Nat Rev Clin Oncol. 2021 Feb;18(2):85-100
pubmed: 32934330
Oncoimmunology. 2016 Dec 14;6(1):e1257452
pubmed: 28197375
Cell Rep. 2017 Apr 4;19(1):101-113
pubmed: 28380350
NPJ Breast Cancer. 2021 Dec 1;7(1):150
pubmed: 34853355
J Immunother Cancer. 2021 Mar;9(3):
pubmed: 33688022
N Engl J Med. 2018 Jul 5;379(1):64-73
pubmed: 29972754
Front Immunol. 2020 May 07;11:784
pubmed: 32457745
J Immunother Cancer. 2019 May 28;7(1):140
pubmed: 31138333
Cell. 2021 Feb 4;184(3):792-809.e23
pubmed: 33545035
Bioact Mater. 2020 Dec 26;6(7):1973-1987
pubmed: 33426371
Nat Commun. 2021 Jan 18;12(1):430
pubmed: 33462228
Cancer Cell. 2005 Nov;8(5):369-80
pubmed: 16286245
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
J Clin Invest. 2020 Nov 2;130(11):5721-5737
pubmed: 32721948
Life Sci Alliance. 2019 Jun 3;2(3):
pubmed: 31160380
Cell. 2018 Aug 23;174(5):1293-1308.e36
pubmed: 29961579
Nat Commun. 2021 Apr 12;12(1):2186
pubmed: 33846305
Ther Adv Med Oncol. 2019 Mar 19;11:1758835919833519
pubmed: 30911337
Stem Cell Res Ther. 2021 Jan 25;12(1):81
pubmed: 33494834
Cancer Discov. 2021 Nov;11(11):2748-2763
pubmed: 34266984
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Br J Cancer. 2018 Jul;119(1):4-11
pubmed: 29808015
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
Cancer Res. 2018 Jan 15;78(2):489-500
pubmed: 29183891
J Clin Oncol. 2022 Jun 1;40(16):1741-1754
pubmed: 35104158
Cancer Cell. 2018 Mar 12;33(3):463-479.e10
pubmed: 29455927
Immunity. 2016 Nov 15;45(5):1122-1134
pubmed: 27851913
J Leukoc Biol. 2009 Nov;86(5):1065-73
pubmed: 19741157
Leukemia. 2021 Jun;35(6):1586-1596
pubmed: 33097838
Cancer. 2018 May 15;124(10):2086-2103
pubmed: 29424936
ESMO Open. 2020 Aug;5(4):
pubmed: 32817130
Nat Commun. 2018 Oct 16;9(1):4297
pubmed: 30327458
Genes Dev. 2011 Dec 1;25(23):2465-79
pubmed: 22156207
Biomark Res. 2020 Nov 11;8(1):64
pubmed: 33292666
BMC Cancer. 2016 Aug 26;16:687
pubmed: 27566250
Lancet. 2021 May 8;397(10286):1750-1769
pubmed: 33812473
Cancer Res. 2006 Jan 15;66(2):605-12
pubmed: 16423985
Front Immunol. 2018 May 30;9:1209
pubmed: 29899747
Nat Rev Cancer. 2020 Mar;20(3):174-186
pubmed: 31980749
Br J Cancer. 2014 Feb 4;110(3):724-32
pubmed: 24335925
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
Pathol Oncol Res. 2014 Jul;20(3):619-24
pubmed: 24414992
Breast Cancer Res. 2021 Oct 29;23(1):99
pubmed: 34715905
Cancer Res. 2018 Dec 15;78(24):6852-6865
pubmed: 30449733
Nat Rev Cancer. 2016 Aug 23;16(9):582-98
pubmed: 27550820
Nat Commun. 2016 Aug 04;7:12237
pubmed: 27488962
J Exp Med. 2018 Dec 3;215(12):3075-3093
pubmed: 30470719
Cell. 2020 Apr 16;181(2):442-459.e29
pubmed: 32302573
PLoS One. 2019 Jun 24;14(6):e0218854
pubmed: 31233557
Sci Transl Med. 2017 May 10;9(389):
pubmed: 28490665
Biomark Res. 2014 Jan 07;2(1):1
pubmed: 24398220
Sci Transl Med. 2011 Nov 9;3(108):108ra113
pubmed: 22072638
Cell. 2019 May 16;177(5):1330-1345.e18
pubmed: 30982598
JCI Insight. 2019 Sep 19;4(18):
pubmed: 31415244
Expert Rev Anticancer Ther. 2012 Dec;12(12):1597-611
pubmed: 23253225
Cold Spring Harb Perspect Med. 2017 Jul 5;7(7):
pubmed: 28213438
Cancer Immunol Immunother. 2019 Mar;68(3):365-377
pubmed: 30523370
Adv Drug Deliv Rev. 2022 Mar;182:114112
pubmed: 35085624
J Exp Med. 2021 Apr 5;218(4):
pubmed: 33561195
BMC Cancer. 2012 Jul 23;12:306
pubmed: 22824040
J Control Release. 2016 Dec 28;244(Pt B):257-268
pubmed: 27616660
Nat Commun. 2021 Feb 9;12(1):877
pubmed: 33563975
Sci Signal. 2016 Feb 16;9(415):ra19
pubmed: 26884601
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2796-801
pubmed: 21825174
N Engl J Med. 2021 Apr 22;384(16):1529-1541
pubmed: 33882206
Trends Cancer. 2020 Jul;6(7):605-618
pubmed: 32610070
Oncotarget. 2021 Jul 06;12(14):1427-1433
pubmed: 34262652